Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Hediger

Nurse Practitioner, Family Springfield, MO Nurse Practitioner

NPI 1316137128 CMS profile 10561820

2230 S Glenstone Ave, Springfield, MO 65804

Open in the dashboard

General payments

$71,169

624 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Hediger of Springfield, MO is reported in the CMS Open Payments database as having received $71,169 across 624 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,687 78
2024 General $7,048 117
2023 General $8,122 121
2022 General $18,997 148
2021 General $28,315 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Hediger
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Laura Hediger were reported at $8,687. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Laura Hediger Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $28,315 $124 $35–$379 $132
2022 $18,997 $141 $44–$430 $149
2023 $8,122 $154 $49–$476 $160
2024 $7,048 $165 $51–$504 $164
2025 $8,687 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $31,617 261 payments
  2. Amgen Inc. $12,759 30 payments
  3. Biohaven Pharmaceuticals, Inc. $8,269 50 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $7,832 56 payments
  5. Pfizer Inc. $4,747 76 payments
  6. Allergan Inc. $3,109 10 payments
  7. Lilly USA, LLC $1,083 51 payments
  8. Lundbeck LLC $831 46 payments
  9. Teva Pharmaceuticals USA, Inc. $298 11 payments
  10. Supernus Pharmaceuticals, Inc. $218 21 payments
  11. Other $405 12 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,806 59 payments
  2. Food and Beverage $9,171 544 payments
  3. Travel and Lodging $1,083 18 payments
  4. Consulting Fee $1,051 2 payments
  5. Education $58 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $31,203 165 payments
  2. NURTEC ODT Primary Care $16,101 106 payments
  3. AIMOVIG $12,759 30 payments
  4. QULIPTA $12,382 140 payments
  5. NURTEC ODT Pain $3,525 69 payments
  6. ZAVZPRET $1,749 52 payments
  7. EMGALITY $975 50 payments
  8. REYVOW $604 30 payments
  9. VYEPTI $500 28 payments
  10. BOTOX $414 23 payments
  11. Other $1,910 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,760

Median for Nurse Practitioner: 389

Drug cost

$1,127,703

Median for Nurse Practitioner: $21,885

Branded share of claims

49.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Emgality Pen Galcanezumab-Gnlm Brand 244 $258,270
Qulipta Atogepant Brand 168 $218,059
Ubrelvy Ubrogepant Brand 156 $180,913
Nurtec Odt Rimegepant Sulfate Brand 168 $177,688
Aimovig Autoinjector Erenumab-Aooe Brand 126 $151,360
Ajovy Autoinjector Fremanezumab-Vfrm Brand 61 $79,623
Emgality Syringe Galcanezumab-Gnlm Brand 12 $21,740
Topiramate Er Topiramate Brand 23 $8,834
Rizatriptan Rizatriptan Benzoate Brand 298 $5,629
Sumatriptan Generic 25 $3,818

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$38,606

Of which drugs: $29,212

Medicare patients

101

Average age 66

Services billed

6,373

80 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 59%
High blood pressure 55%
Depression 40%
Chronic kidney disease 25%
Diabetes 24%
Ischemic heart disease 21%
Osteoporosis 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 6,000 $29,188

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $3,687
$3,687 156 —
ZAVZPRET
  • PFIZER INC. $1,263
$1,263 — —
QULIPTA
  • AbbVie, Inc. $945
$945 168 —
NURTEC ODT
  • PFIZER INC. $555
$555 168 —
EMGALITY
  • Lilly USA, LLC $225
$225 256 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record